William Blair Starts Adamas Pharmaceuticals (ADMS) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St set to snap three-day losing streak as stocks reclaim some shine
- Oil rises 1%, as US-Iran strikes risk limiting already impaired supplies
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
Credit Suisse Starts Adamas Pharmaceuticals (ADMS) at Outperform
May 5, 2014 7:31 AM EDTCredit Suisse initiated coverage on Adamas Pharmaceuticals (NASDAQ: ADMS) with an Outperform rating and a price target of $26.00.
For an analyst ratings summary and ratings history on Adamas Pharmaceuticals click here. For more ratings news on Adamas Pharmaceuticals click here.
Shares of Adamas Pharmaceuticals closed at $20.01 yesterday.
... MorePiper Jaffray Starts Adamas Pharmaceuticals (ADMS) at Overweight
May 5, 2014 7:11 AM EDTPiper Jaffray initiates coverage on Adamas Pharmaceuticals (NASDAQ: ADMS) with a Overweight rating and a price target of $32.00.
Analyst David Amsellem comments, "Adamas has the potential to generate compelling cash flows over the long-term, driven by ADS-5102, an extended release (ER) form of amantadine for... More
Needham & Company Starts Adamas Pharmaceuticals (ADMS) at Buy
May 5, 2014 6:21 AM EDTNeedham & Company initiates coverage on Adamas Pharmaceuticals (NASDAQ: ADMS) with a Buy rating and a price target of $33.00.
Analyst Elliot Wilbur comments, "We are initiating coverage of Adamas Pharmaceuticals, a specialty pharma play with a validated platform for developing and commercializing pharmacokinetically enhanced... More
